Introduction:
Intracranial haemorrhage in children with inherited bleeding disorders is a potentially life-threatening complication and presents a significant therapeutic challenge.
Aim:
To define the characteristics, management and outcomes of intracranial haemorrhage presenting in UK children ≤16 years of age with inherited bleeding disorders from 2003 to 2015.
Method: Retrospective analysis of children treated at UK haemophilia centres.
Results:
Of 66 children presenting with Intracranial haemorrhage (ICH), 82% had haemophilia A or B, 3% VWD and 15% a rare IBD. The IBD was a severe phenotype in 91%. The rates of ICH were 6.4 and 4.2 per 1000 patient years for haemophilia A and B, respectively. Median age at presentation was 4 months (33% neonates; 91% children <2 years of age). In neonates, delivery was spontaneous vaginal (SV) in 11, instrumental in 6, caesarean in 4 and unknown in 1. In children with haemophilia, the risk of ICH after instrumental delivery was 10.6 times greater than after SV delivery.
Trauma was more common in children >2 years (67%) than in children 1 month to 2 years (18%; P = .027). Prior to ICH, only 4.5% of children were on prophylaxis. 6% of haemophiliacs had an inhibitor. The median duration of initial replacement therapy was 15 days. Mortality was 13.5%. Neurological sequelae occurred in 39% of survivors, being more common following intracerebral bleeding. In haemophilia survivors, 52% subsequently developed a FVIII inhibitor.
Conclusion:
Intracranial haemorrhage occurs most frequently in children with severe IBDs, during the first 2 years of life and in children not receiving prophylaxis.
Intracranial haemorrhage often occurs without documented trauma.
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The incidence of ICH in older children with haemophilia has been estimated previously at 2.02-7.96 per 1000 patient years, 2 but is less well defined in the modern era where, at least in the developed world, prophylaxis commenced early in childhood is widespread and may offer protection against all types of bleeding. 4, 14 In addition, published reports have varied significantly in terms of age inclusion criteria which may affect risk factor identification in specific age groups.
Historically, mortality following ICH was extremely high and even in more recent studies occurs in 20%-25%, with neurological sequelae commonly reported. 4, 5, [15] [16] [17] Improvements in diagnosis, management and the widespread use of prophylaxis, particularly in severe haemophilia, might be expected to have influenced both the occurrence and the outcomes of ICH in children with IBDs. The aim of this study was to define the 
| ME THODS
In this retrospective national cohort study, ICH in children with IBDs presenting between January 2003 and December 2015 were reported to the UK Haemophilia Centre Doctors' Organisation (UKHCDO) National Haemophilia Database (NHD), which collates data from all haemophilia centres under an agreement with the UK Data Protection
Registrar. Follow-up data were obtained from reporting centres on diagnosis, presentation, risk factors, management and outcomes.
| Statistical analysis
Diagnosis-specific incidence was calculated using data from chil- Of the 66 children with any reported ICH, the underlying diagnosis was haemophilia in 54 (82%) and a rare IBD in 10 (15%). Only 2 children (3%) had VWD, and there were no reported episodes of ICH in children with platelet disorders. In 60 children (91%), the underlying IBD was classified as severe. 
| Age at ICH presentation
Of the 66 children with ICH, the median age at presentation of first 0.9%), increasing to 3.6% at 2 years of age (haemophilia A: 3.7%, haemophilia B: 2.7%) and 3.9% at 10 years of age (haemophilia A:
4.1%, haemophilia B: 2.7%).
There was no significant difference in the distribution of underlying diagnosis in those presenting at ≤1 month of age or >1 month of age (P = .75). (Table 2 ). Sub-dural and intracerebral ICH were the most frequent sites of bleeding, both occurring in 48% of children.
| Risk factors for ICH
Considering the 54 children with haemophilia, an inhibitor prior to presentation with ICH was reported in 3 children (6%). Fifty-one (94%) of children with haemophilia were not on prophylaxis prior to first ICH. Of the remaining 3 children with haemophilia who were receiving prophylaxis, all were receiving FVII for haemophilia A and only 1 was under 2 years of age. One child with haemophilia A and an inhibitor was receiving regular treatment with activated prothrombinase complex concentrate. None of the 10 children with a rare ICH were receiving prophylaxis before first ICH. Of the 66 children with ICH, 1 (1.5%) had a family history of ICH.
| Neonatal ICH and Mode of Delivery
Of the 22 children who presented with ICH as neonates (18 with haemophilia, 2 with rare IBD), only 3 (14%) were preterm (≤36 weeks gestation). Of the 12 children with no prior family history of an IBD, 6 (50%) had an instrumental delivery (Table 3) . In those with a positive family history of an IBD, there were no instrumental deliveries; however, ICH occurred in 2 children despite planned caesarean delivery. Intracranial haemorrhage also followed elective caesarean in 1 child with no family history.
Eighteen children with haemophilia presented with ICH as neonates. Compared with non-ICH neonates (N = 254), using spontaneous vaginal delivery without instrumentation as the reference group and adjusting for family history of haemophilia, they were 10.6 times more likely to have been delivered with instrumentation, (95% CI 2.0-54.7, P < .005). Using the same reference group, the risk associated with all caesarean deliveries was 0.6 (0.2 -1.8, P = .3), 0.6 (0.2-2.1, P = .4) for elective CS and 0.4 (0.1-2.9, P = .4) for emergency CS.
| Trauma in children presenting after 1 month of age
Of the 44 children who presented with ICH after the neonatal period, trauma before presentation was reported for 11 (25%) children, 2/24 (8%) children aged 1-6 months of age; 7/32 (18%) children aged Intracranial haemorrhage in children with severe haemophilia 1-24 months of age and 4/6 (67%) children older than 24 months (P = .027). In 2 children aged 1-6 months, trauma was secondary to nonaccidental injury (NAI).
| MANAG EMENT
Of the 66 children with ICH, 22 (33%) underwent surgical intervention.
This comprised craniotomy and evacuation in 16 children and insertion of a VP shunt or drain in 6 children. Excluding those who died during the first few days of treatment, the median duration of initial replacement therapy was 15 days (range 5-42 days; IQR 14-28 days).
| OUTCOME S

| Mortality
There were 9 deaths associated with ICH, giving an overall mortality of 13.5%. Of the 9 children who died, 8 children had haemophilia A and 1 had severe FVII deficiency. Seven deaths occurred within the first week after ICH, while the other 2 occurred later.
| Neurological morbidity
Of the 59 children who survived the initial event (median followup 6.9 years, range 116 days-12.8 years), 23 (39%) were reported to have neurological sequelae. This comprised motor weakness (5), cognitive problems (9), combined motor and cognitive problems (6), seizures (6), partial deafness (1) and visual problems (1). Poor neurological outcome was more common following intracerebral bleeding 16/26 (62%) as compared to those with subdural bleeds 6/30 (20%) P = .002.
| Recurrent ICH
Three of 59 (5%) children who survived the initial event experienced at least 1 further ICH. Two children had 2 episodes, and 1 child had a further 3 episodes. All recurrent bleeds occurred in children with haemophilia, and in 2, this was associated with an inhibitor.
| Inhibitor development in children with Haemophilia A
Of the 47 haemophilia A children with ICH, 40 survived and were available for follow-up monitoring. Overall 21 (52%) developed inhibitors after initial FVIII replacement, including 7/14 (50%) treated under 1 month of age.
| D ISCUSS I ON
In this cohort study, we have evaluated the clinical characteristics, we were unable to calculate reliable incidence estimates for ICH in these disorders, previous case series suggest that the absolute risk of ICH in rare IBD may be individually high, particularly for severe FXIII deficiency. Our finding that ICH was uncommon in children with VWD and absent in these with inherited platelet disorders is in keeping with the low number of reported cases, suggesting that ICH is indeed rare in patients with disorders of primary haemostasis. 21, 22 In our cohort, more than 90% of ICH cases had an IBD that was classified as severe. This is similar to data from Traivaree et al The predominance of ICH in young children in our cohort is highlighted by the median age at presentation of 4 months, with 91% presenting under 2 years of age. The predominance of ICH in younger children has not been a consistent finding, and while most studies report neonates to be at high risk, the relationship between ICH and age is less clear beyond the neonatal period. 1, 5 Again, the age distribution in our study may reflect the protective effect of prophylaxis which in the UK is commenced before the third birthday in >90% of children with severe haemophilia. 23 Earlier onset of prophylaxis might therefore have the potential to reduce the risk of ICH.
Neonatal ICH, particularly in haemophilia, has been the focus of several previous publications. Beyond the neonatal period trauma has often been reported as a risk factor for ICH. 4 In this study, there was a significantly higher incidence of reported trauma in children over 2 years of age. The absence of reported trauma was particularly striking in the youngest children, many of whom were premobile. While the absence of prophylaxis is likely to be contributory, it is possible that other undefined factors relating to the developing brain may also contribute. It is also important to exclude nonaccidental injury, which can coexist with IBDs as was documented in 2 cases in this cohort.
Mortality following ICH in this study was 13.5%, with most deaths occurring early. In most contemporary studies, mortality following ICH has been around 20%; however, this often includes data from both adults and children where mortality rates may differ. More recently Witmer et al 7 reported data from the US covering the period 2002-2011 where mortality in males with haemophilia aged <21 years with ICH was much lower at 2.5%. In a similar study by the same authors, mortality in children was lower than in adults, although this study did not include children under 2 years of age. 4 It is not clear why mortality in our series is higher; however, mortality was highest in neonates who may be at particularly high risk and accounted for 33% of reported cases. Poor neuro-cognitive outcomes were reported in 39% and were more common following intracerebral bleeds, emphasizing the need for structured neuro-cognitive follow-up. 17 Intracranial haemorrhage management includes high-dose factor replacement therapy which represents an intensive exposure. In haemophilia A, this was been shown to be a risk factor for inhibitor development, particularly when associated with initial exposure to FVIII. 32, 33 Consistent with this, haemophilia A survivors in this study had a higher than expected risk of inhibitor development.
The main strength of this study is that it represents a national cohort and consists of a relatively large number of cases across all IBDs. Given the specialized nature of care in the UK, it is very unlikely that cases would have been managed out with haemophilia centres and data collection is therefore likely to be a true reflection of cases presenting during this period. The only potential limitation might relate to early deaths occurring prior to referral for specialist management.
| CON CLUS ION
In conclusion, in this UK, cohort study ICH occurred most frequently in children with severe IBDs, during the first 2 years of life and in children not receiving prophylaxis. Intracranial haemorrhage often occurred without documented trauma and was associated with significant morbidity and mortality.
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